Podcast appearances and mentions of Johanna C Bendell

Go online to PeerView.com/QAF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovations in the management of pancreatic cancer have increased hope for patients with this aggressive malignancy. New and promising treatment advances include novel chemotherapy platforms, such as gemcitabine/nab-paclitaxel and nanoliposomal irinotecan–based regimens; targeted systemic approaches, including PARP inhibitors, stroma-targeting agents, and immunotherapies; and other novel modalities, such as tumor treating fields. Modern chemotherapy regimens have improved outcomes for patients in the first- and second-line advanced settings, while practice-changing data on targeted strategies continue to emerge, offering more personalized prospective treatment plans. How has the treatment of pancreatic cancer changed in the first- and second-line metastatic settings? What are the roles of mutation testing and PARP inhibitors in the frontline maintenance setting? What novel solutions are on the horizon for unmet clinical needs in locally advanced and metastatic settings? Through collaboration with Let's Win, an affiliate of the Lustgarten Foundation, this PeerView Live on-demand activity answers these key questions and others with a “How I Think, How I Treat” educational design, providing a personal look at the way experts consider important new and emerging data while navigating the current pancreatic cancer treatment landscape to enhance patient care and outcomes. Upon completion of this activity, participants should be better able to: Review the latest clinical evidence on use of novel chemotherapy platforms, immunotherapy, PARP inhibitors, stromal-targeting agents, and tumor treating field therapy, among others, for pancreatic cancer, Examine the emerging role of PARP inhibitors in frontline, maintenance setting for patients with BRCA-mutant pancreatic cancer, Summarize ongoing clinical trials investigating innovative therapies, including immunotherapy, tumor treating fields, combinations with chemotherapy platforms, among others, for patients with pancreatic cancer, Recommend optimal treatment plans, including the enrollment of clinical trials, across multiple lines of therapy for patients with advanced pancreatic cancer based on validated evidence, guideline recommendations, and disease- and patient-specific factors

Go online to PeerView.com/QAF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovations in the management of pancreatic cancer have increased hope for patients with this aggressive malignancy. New and promising treatment advances include novel chemotherapy platforms, such as gemcitabine/nab-paclitaxel and nanoliposomal irinotecan–based regimens; targeted systemic approaches, including PARP inhibitors, stroma-targeting agents, and immunotherapies; and other novel modalities, such as tumor treating fields. Modern chemotherapy regimens have improved outcomes for patients in the first- and second-line advanced settings, while practice-changing data on targeted strategies continue to emerge, offering more personalized prospective treatment plans. How has the treatment of pancreatic cancer changed in the first- and second-line metastatic settings? What are the roles of mutation testing and PARP inhibitors in the frontline maintenance setting? What novel solutions are on the horizon for unmet clinical needs in locally advanced and metastatic settings? Through collaboration with Let's Win, an affiliate of the Lustgarten Foundation, this PeerView Live on-demand activity answers these key questions and others with a “How I Think, How I Treat” educational design, providing a personal look at the way experts consider important new and emerging data while navigating the current pancreatic cancer treatment landscape to enhance patient care and outcomes. Upon completion of this activity, participants should be better able to: Review the latest clinical evidence on use of novel chemotherapy platforms, immunotherapy, PARP inhibitors, stromal-targeting agents, and tumor treating field therapy, among others, for pancreatic cancer, Examine the emerging role of PARP inhibitors in frontline, maintenance setting for patients with BRCA-mutant pancreatic cancer, Summarize ongoing clinical trials investigating innovative therapies, including immunotherapy, tumor treating fields, combinations with chemotherapy platforms, among others, for patients with pancreatic cancer, Recommend optimal treatment plans, including the enrollment of clinical trials, across multiple lines of therapy for patients with advanced pancreatic cancer based on validated evidence, guideline recommendations, and disease- and patient-specific factors

Go online to PeerView.com/QAF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovations in the management of pancreatic cancer have increased hope for patients with this aggressive malignancy. New and promising treatment advances include novel chemotherapy platforms, such as gemcitabine/nab-paclitaxel and nanoliposomal irinotecan–based regimens; targeted systemic approaches, including PARP inhibitors, stroma-targeting agents, and immunotherapies; and other novel modalities, such as tumor treating fields. Modern chemotherapy regimens have improved outcomes for patients in the first- and second-line advanced settings, while practice-changing data on targeted strategies continue to emerge, offering more personalized prospective treatment plans. How has the treatment of pancreatic cancer changed in the first- and second-line metastatic settings? What are the roles of mutation testing and PARP inhibitors in the frontline maintenance setting? What novel solutions are on the horizon for unmet clinical needs in locally advanced and metastatic settings? Through collaboration with Let's Win, an affiliate of the Lustgarten Foundation, this PeerView Live on-demand activity answers these key questions and others with a “How I Think, How I Treat” educational design, providing a personal look at the way experts consider important new and emerging data while navigating the current pancreatic cancer treatment landscape to enhance patient care and outcomes. Upon completion of this activity, participants should be better able to: Review the latest clinical evidence on use of novel chemotherapy platforms, immunotherapy, PARP inhibitors, stromal-targeting agents, and tumor treating field therapy, among others, for pancreatic cancer, Examine the emerging role of PARP inhibitors in frontline, maintenance setting for patients with BRCA-mutant pancreatic cancer, Summarize ongoing clinical trials investigating innovative therapies, including immunotherapy, tumor treating fields, combinations with chemotherapy platforms, among others, for patients with pancreatic cancer, Recommend optimal treatment plans, including the enrollment of clinical trials, across multiple lines of therapy for patients with advanced pancreatic cancer based on validated evidence, guideline recommendations, and disease- and patient-specific factors

Go online to PeerView.com/QAF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovations in the management of pancreatic cancer have increased hope for patients with this aggressive malignancy. New and promising treatment advances include novel chemotherapy platforms, such as gemcitabine/nab-paclitaxel and nanoliposomal irinotecan–based regimens; targeted systemic approaches, including PARP inhibitors, stroma-targeting agents, and immunotherapies; and other novel modalities, such as tumor treating fields. Modern chemotherapy regimens have improved outcomes for patients in the first- and second-line advanced settings, while practice-changing data on targeted strategies continue to emerge, offering more personalized prospective treatment plans. How has the treatment of pancreatic cancer changed in the first- and second-line metastatic settings? What are the roles of mutation testing and PARP inhibitors in the frontline maintenance setting? What novel solutions are on the horizon for unmet clinical needs in locally advanced and metastatic settings? Through collaboration with Let's Win, an affiliate of the Lustgarten Foundation, this PeerView Live on-demand activity answers these key questions and others with a “How I Think, How I Treat” educational design, providing a personal look at the way experts consider important new and emerging data while navigating the current pancreatic cancer treatment landscape to enhance patient care and outcomes. Upon completion of this activity, participants should be better able to: Review the latest clinical evidence on use of novel chemotherapy platforms, immunotherapy, PARP inhibitors, stromal-targeting agents, and tumor treating field therapy, among others, for pancreatic cancer, Examine the emerging role of PARP inhibitors in frontline, maintenance setting for patients with BRCA-mutant pancreatic cancer, Summarize ongoing clinical trials investigating innovative therapies, including immunotherapy, tumor treating fields, combinations with chemotherapy platforms, among others, for patients with pancreatic cancer, Recommend optimal treatment plans, including the enrollment of clinical trials, across multiple lines of therapy for patients with advanced pancreatic cancer based on validated evidence, guideline recommendations, and disease- and patient-specific factors

Go online to PeerView.com/QAF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovations in the management of pancreatic cancer have increased hope for patients with this aggressive malignancy. New and promising treatment advances include novel chemotherapy platforms, such as gemcitabine/nab-paclitaxel and nanoliposomal irinotecan–based regimens; targeted systemic approaches, including PARP inhibitors, stroma-targeting agents, and immunotherapies; and other novel modalities, such as tumor treating fields. Modern chemotherapy regimens have improved outcomes for patients in the first- and second-line advanced settings, while practice-changing data on targeted strategies continue to emerge, offering more personalized prospective treatment plans. How has the treatment of pancreatic cancer changed in the first- and second-line metastatic settings? What are the roles of mutation testing and PARP inhibitors in the frontline maintenance setting? What novel solutions are on the horizon for unmet clinical needs in locally advanced and metastatic settings? Through collaboration with Let's Win, an affiliate of the Lustgarten Foundation, this PeerView Live on-demand activity answers these key questions and others with a “How I Think, How I Treat” educational design, providing a personal look at the way experts consider important new and emerging data while navigating the current pancreatic cancer treatment landscape to enhance patient care and outcomes. Upon completion of this activity, participants should be better able to: Review the latest clinical evidence on use of novel chemotherapy platforms, immunotherapy, PARP inhibitors, stromal-targeting agents, and tumor treating field therapy, among others, for pancreatic cancer, Examine the emerging role of PARP inhibitors in frontline, maintenance setting for patients with BRCA-mutant pancreatic cancer, Summarize ongoing clinical trials investigating innovative therapies, including immunotherapy, tumor treating fields, combinations with chemotherapy platforms, among others, for patients with pancreatic cancer, Recommend optimal treatment plans, including the enrollment of clinical trials, across multiple lines of therapy for patients with advanced pancreatic cancer based on validated evidence, guideline recommendations, and disease- and patient-specific factors

Go online to PeerView.com/QAF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovations in the management of pancreatic cancer have increased hope for patients with this aggressive malignancy. New and promising treatment advances include novel chemotherapy platforms, such as gemcitabine/nab-paclitaxel and nanoliposomal irinotecan–based regimens; targeted systemic approaches, including PARP inhibitors, stroma-targeting agents, and immunotherapies; and other novel modalities, such as tumor treating fields. Modern chemotherapy regimens have improved outcomes for patients in the first- and second-line advanced settings, while practice-changing data on targeted strategies continue to emerge, offering more personalized prospective treatment plans. How has the treatment of pancreatic cancer changed in the first- and second-line metastatic settings? What are the roles of mutation testing and PARP inhibitors in the frontline maintenance setting? What novel solutions are on the horizon for unmet clinical needs in locally advanced and metastatic settings? Through collaboration with Let's Win, an affiliate of the Lustgarten Foundation, this PeerView Live on-demand activity answers these key questions and others with a “How I Think, How I Treat” educational design, providing a personal look at the way experts consider important new and emerging data while navigating the current pancreatic cancer treatment landscape to enhance patient care and outcomes. Upon completion of this activity, participants should be better able to: Review the latest clinical evidence on use of novel chemotherapy platforms, immunotherapy, PARP inhibitors, stromal-targeting agents, and tumor treating field therapy, among others, for pancreatic cancer, Examine the emerging role of PARP inhibitors in frontline, maintenance setting for patients with BRCA-mutant pancreatic cancer, Summarize ongoing clinical trials investigating innovative therapies, including immunotherapy, tumor treating fields, combinations with chemotherapy platforms, among others, for patients with pancreatic cancer, Recommend optimal treatment plans, including the enrollment of clinical trials, across multiple lines of therapy for patients with advanced pancreatic cancer based on validated evidence, guideline recommendations, and disease- and patient-specific factors

Go online to PeerView.com/QAF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovations in the management of pancreatic cancer have increased hope for patients with this aggressive malignancy. New and promising treatment advances include novel chemotherapy platforms, such as gemcitabine/nab-paclitaxel and nanoliposomal irinotecan–based regimens; targeted systemic approaches, including PARP inhibitors, stroma-targeting agents, and immunotherapies; and other novel modalities, such as tumor treating fields. Modern chemotherapy regimens have improved outcomes for patients in the first- and second-line advanced settings, while practice-changing data on targeted strategies continue to emerge, offering more personalized prospective treatment plans. How has the treatment of pancreatic cancer changed in the first- and second-line metastatic settings? What are the roles of mutation testing and PARP inhibitors in the frontline maintenance setting? What novel solutions are on the horizon for unmet clinical needs in locally advanced and metastatic settings? Through collaboration with Let's Win, an affiliate of the Lustgarten Foundation, this PeerView Live on-demand activity answers these key questions and others with a “How I Think, How I Treat” educational design, providing a personal look at the way experts consider important new and emerging data while navigating the current pancreatic cancer treatment landscape to enhance patient care and outcomes. Upon completion of this activity, participants should be better able to: Review the latest clinical evidence on use of novel chemotherapy platforms, immunotherapy, PARP inhibitors, stromal-targeting agents, and tumor treating field therapy, among others, for pancreatic cancer, Examine the emerging role of PARP inhibitors in frontline, maintenance setting for patients with BRCA-mutant pancreatic cancer, Summarize ongoing clinical trials investigating innovative therapies, including immunotherapy, tumor treating fields, combinations with chemotherapy platforms, among others, for patients with pancreatic cancer, Recommend optimal treatment plans, including the enrollment of clinical trials, across multiple lines of therapy for patients with advanced pancreatic cancer based on validated evidence, guideline recommendations, and disease- and patient-specific factors

Go online to PeerView.com/QAF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovations in the management of pancreatic cancer have increased hope for patients with this aggressive malignancy. New and promising treatment advances include novel chemotherapy platforms, such as gemcitabine/nab-paclitaxel and nanoliposomal irinotecan–based regimens; targeted systemic approaches, including PARP inhibitors, stroma-targeting agents, and immunotherapies; and other novel modalities, such as tumor treating fields. Modern chemotherapy regimens have improved outcomes for patients in the first- and second-line advanced settings, while practice-changing data on targeted strategies continue to emerge, offering more personalized prospective treatment plans. How has the treatment of pancreatic cancer changed in the first- and second-line metastatic settings? What are the roles of mutation testing and PARP inhibitors in the frontline maintenance setting? What novel solutions are on the horizon for unmet clinical needs in locally advanced and metastatic settings? Through collaboration with Let's Win, an affiliate of the Lustgarten Foundation, this PeerView Live on-demand activity answers these key questions and others with a “How I Think, How I Treat” educational design, providing a personal look at the way experts consider important new and emerging data while navigating the current pancreatic cancer treatment landscape to enhance patient care and outcomes. Upon completion of this activity, participants should be better able to: Review the latest clinical evidence on use of novel chemotherapy platforms, immunotherapy, PARP inhibitors, stromal-targeting agents, and tumor treating field therapy, among others, for pancreatic cancer, Examine the emerging role of PARP inhibitors in frontline, maintenance setting for patients with BRCA-mutant pancreatic cancer, Summarize ongoing clinical trials investigating innovative therapies, including immunotherapy, tumor treating fields, combinations with chemotherapy platforms, among others, for patients with pancreatic cancer, Recommend optimal treatment plans, including the enrollment of clinical trials, across multiple lines of therapy for patients with advanced pancreatic cancer based on validated evidence, guideline recommendations, and disease- and patient-specific factors

Genomic Assays in the “Real” Oncology World: Exploring the Role of Genomic Testing in Guiding Treatment for Patients with Advanced Breast, Colorectal and Prostate Cancers. A roundtable discussion featuring Emmanuel S Antonarakis, MD, Johanna C Bendell, MD, Ian E Krop, MD, PhD and Andrew McKenzie, PhD moderated by Neil Love, MD. Produced by Research To Practice.

Genomic Assays in the “Real” Oncology World: Exploring the Role of Genomic Testing in Guiding Treatment for Patients with Advanced Breast, Colorectal and Prostate Cancers. A roundtable discussion featuring Emmanuel S Antonarakis, MD, Johanna C Bendell, MD, Ian E Krop, MD, PhD and Andrew McKenzie, PhD moderated by Neil Love, MD. Produced by Research To Practice.

Go online to PeerView.com/RRU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Pancreatic cancer has retained its fearsome reputation amidst the clinical advances made in recent years in other solid tumor settings, and it is now the fourth leading cause of cancer death in men and women in the United States. But recently, new science has taken important steps in meeting the challenges posed by this disease. Beginning with the validation of modern chemotherapy platforms, which now can be sequenced to improve clinical benefits, clinicians are increasingly able to select more potent—and soon, more targeted—options for disease management. In the wake of these advances, other innovative therapies are being rapidly developed, from stroma- and BRCA-targeting agents, to immunotherapy and tumor treating fields. In this PeerView CaseBook on-demand activity based on a recent live symposium held at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, our expert panel profiles the modern management of pancreatic cancer, including the evidence for more personalized approaches to treatment decision-making across the disease spectrum. The panelists highlight new directions in therapeutic sequencing, explore the role of clinical trials as a driver for validating innovative strategies, and use real-world cases to crystalize strategies for initial therapy selection and sequencing, the function of biomarker testing, and patient referral to clinical trials. This engaging CaseBook activity also highlights important “patient voice” materials developed in collaboration with Let's Win, an online community (letswinpc.org) for sharing information about innovative, science-based treatments for Pancreatic Cancer. Let's Win is an affiliate of the Lustgarten Foundation. Upon completion of this activity, participants will be able to: Summarize recent evidence on the use of modern cytotoxic platforms and chemotherapy sequencing approaches, targeted agents, and tumor treating field therapy, among others, in the setting of advanced pancreatic cancer, Recommend appropriate therapeutic platforms across multiple lines of therapy for patients with advanced pancreatic cancer based on available evidence, guideline recommendations, and disease- and patient-specific characteristics, Identify patients with pancreatic cancer who are candidates for experimental therapy in a clinical trial, Manage adverse events associated with established cytotoxic and emerging therapies for pancreatic cancer.

Go online to PeerView.com/RRU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Pancreatic cancer has retained its fearsome reputation amidst the clinical advances made in recent years in other solid tumor settings, and it is now the fourth leading cause of cancer death in men and women in the United States. But recently, new science has taken important steps in meeting the challenges posed by this disease. Beginning with the validation of modern chemotherapy platforms, which now can be sequenced to improve clinical benefits, clinicians are increasingly able to select more potent—and soon, more targeted—options for disease management. In the wake of these advances, other innovative therapies are being rapidly developed, from stroma- and BRCA-targeting agents, to immunotherapy and tumor treating fields. In this PeerView CaseBook on-demand activity based on a recent live symposium held at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, our expert panel profiles the modern management of pancreatic cancer, including the evidence for more personalized approaches to treatment decision-making across the disease spectrum. The panelists highlight new directions in therapeutic sequencing, explore the role of clinical trials as a driver for validating innovative strategies, and use real-world cases to crystalize strategies for initial therapy selection and sequencing, the function of biomarker testing, and patient referral to clinical trials. This engaging CaseBook activity also highlights important “patient voice” materials developed in collaboration with Let's Win, an online community (letswinpc.org) for sharing information about innovative, science-based treatments for Pancreatic Cancer. Let's Win is an affiliate of the Lustgarten Foundation. Upon completion of this activity, participants will be able to: Summarize recent evidence on the use of modern cytotoxic platforms and chemotherapy sequencing approaches, targeted agents, and tumor treating field therapy, among others, in the setting of advanced pancreatic cancer, Recommend appropriate therapeutic platforms across multiple lines of therapy for patients with advanced pancreatic cancer based on available evidence, guideline recommendations, and disease- and patient-specific characteristics, Identify patients with pancreatic cancer who are candidates for experimental therapy in a clinical trial, Manage adverse events associated with established cytotoxic and emerging therapies for pancreatic cancer.

Go online to PeerView.com/RRU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Pancreatic cancer has retained its fearsome reputation amidst the clinical advances made in recent years in other solid tumor settings, and it is now the fourth leading cause of cancer death in men and women in the United States. But recently, new science has taken important steps in meeting the challenges posed by this disease. Beginning with the validation of modern chemotherapy platforms, which now can be sequenced to improve clinical benefits, clinicians are increasingly able to select more potent—and soon, more targeted—options for disease management. In the wake of these advances, other innovative therapies are being rapidly developed, from stroma- and BRCA-targeting agents, to immunotherapy and tumor treating fields. In this PeerView CaseBook on-demand activity based on a recent live symposium held at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, our expert panel profiles the modern management of pancreatic cancer, including the evidence for more personalized approaches to treatment decision-making across the disease spectrum. The panelists highlight new directions in therapeutic sequencing, explore the role of clinical trials as a driver for validating innovative strategies, and use real-world cases to crystalize strategies for initial therapy selection and sequencing, the function of biomarker testing, and patient referral to clinical trials. This engaging CaseBook activity also highlights important “patient voice” materials developed in collaboration with Let's Win, an online community (letswinpc.org) for sharing information about innovative, science-based treatments for Pancreatic Cancer. Let's Win is an affiliate of the Lustgarten Foundation. Upon completion of this activity, participants will be able to: Summarize recent evidence on the use of modern cytotoxic platforms and chemotherapy sequencing approaches, targeted agents, and tumor treating field therapy, among others, in the setting of advanced pancreatic cancer, Recommend appropriate therapeutic platforms across multiple lines of therapy for patients with advanced pancreatic cancer based on available evidence, guideline recommendations, and disease- and patient-specific characteristics, Identify patients with pancreatic cancer who are candidates for experimental therapy in a clinical trial, Manage adverse events associated with established cytotoxic and emerging therapies for pancreatic cancer.

Go online to PeerView.com/RRU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Pancreatic cancer has retained its fearsome reputation amidst the clinical advances made in recent years in other solid tumor settings, and it is now the fourth leading cause of cancer death in men and women in the United States. But recently, new science has taken important steps in meeting the challenges posed by this disease. Beginning with the validation of modern chemotherapy platforms, which now can be sequenced to improve clinical benefits, clinicians are increasingly able to select more potent—and soon, more targeted—options for disease management. In the wake of these advances, other innovative therapies are being rapidly developed, from stroma- and BRCA-targeting agents, to immunotherapy and tumor treating fields. In this PeerView CaseBook on-demand activity based on a recent live symposium held at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, our expert panel profiles the modern management of pancreatic cancer, including the evidence for more personalized approaches to treatment decision-making across the disease spectrum. The panelists highlight new directions in therapeutic sequencing, explore the role of clinical trials as a driver for validating innovative strategies, and use real-world cases to crystalize strategies for initial therapy selection and sequencing, the function of biomarker testing, and patient referral to clinical trials. This engaging CaseBook activity also highlights important “patient voice” materials developed in collaboration with Let's Win, an online community (letswinpc.org) for sharing information about innovative, science-based treatments for Pancreatic Cancer. Let's Win is an affiliate of the Lustgarten Foundation. Upon completion of this activity, participants will be able to: Summarize recent evidence on the use of modern cytotoxic platforms and chemotherapy sequencing approaches, targeted agents, and tumor treating field therapy, among others, in the setting of advanced pancreatic cancer, Recommend appropriate therapeutic platforms across multiple lines of therapy for patients with advanced pancreatic cancer based on available evidence, guideline recommendations, and disease- and patient-specific characteristics, Identify patients with pancreatic cancer who are candidates for experimental therapy in a clinical trial, Manage adverse events associated with established cytotoxic and emerging therapies for pancreatic cancer.

Go online to PeerView.com/RRU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Pancreatic cancer has retained its fearsome reputation amidst the clinical advances made in recent years in other solid tumor settings, and it is now the fourth leading cause of cancer death in men and women in the United States. But recently, new science has taken important steps in meeting the challenges posed by this disease. Beginning with the validation of modern chemotherapy platforms, which now can be sequenced to improve clinical benefits, clinicians are increasingly able to select more potent—and soon, more targeted—options for disease management. In the wake of these advances, other innovative therapies are being rapidly developed, from stroma- and BRCA-targeting agents, to immunotherapy and tumor treating fields. In this PeerView CaseBook on-demand activity based on a recent live symposium held at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, our expert panel profiles the modern management of pancreatic cancer, including the evidence for more personalized approaches to treatment decision-making across the disease spectrum. The panelists highlight new directions in therapeutic sequencing, explore the role of clinical trials as a driver for validating innovative strategies, and use real-world cases to crystalize strategies for initial therapy selection and sequencing, the function of biomarker testing, and patient referral to clinical trials. This engaging CaseBook activity also highlights important “patient voice” materials developed in collaboration with Let's Win, an online community (letswinpc.org) for sharing information about innovative, science-based treatments for Pancreatic Cancer. Let's Win is an affiliate of the Lustgarten Foundation. Upon completion of this activity, participants will be able to: Summarize recent evidence on the use of modern cytotoxic platforms and chemotherapy sequencing approaches, targeted agents, and tumor treating field therapy, among others, in the setting of advanced pancreatic cancer, Recommend appropriate therapeutic platforms across multiple lines of therapy for patients with advanced pancreatic cancer based on available evidence, guideline recommendations, and disease- and patient-specific characteristics, Identify patients with pancreatic cancer who are candidates for experimental therapy in a clinical trial, Manage adverse events associated with established cytotoxic and emerging therapies for pancreatic cancer.

Go online to PeerView.com/RRU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Pancreatic cancer has retained its fearsome reputation amidst the clinical advances made in recent years in other solid tumor settings, and it is now the fourth leading cause of cancer death in men and women in the United States. But recently, new science has taken important steps in meeting the challenges posed by this disease. Beginning with the validation of modern chemotherapy platforms, which now can be sequenced to improve clinical benefits, clinicians are increasingly able to select more potent—and soon, more targeted—options for disease management. In the wake of these advances, other innovative therapies are being rapidly developed, from stroma- and BRCA-targeting agents, to immunotherapy and tumor treating fields. In this PeerView CaseBook on-demand activity based on a recent live symposium held at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, our expert panel profiles the modern management of pancreatic cancer, including the evidence for more personalized approaches to treatment decision-making across the disease spectrum. The panelists highlight new directions in therapeutic sequencing, explore the role of clinical trials as a driver for validating innovative strategies, and use real-world cases to crystalize strategies for initial therapy selection and sequencing, the function of biomarker testing, and patient referral to clinical trials. This engaging CaseBook activity also highlights important “patient voice” materials developed in collaboration with Let's Win, an online community (letswinpc.org) for sharing information about innovative, science-based treatments for Pancreatic Cancer. Let's Win is an affiliate of the Lustgarten Foundation. Upon completion of this activity, participants will be able to: Summarize recent evidence on the use of modern cytotoxic platforms and chemotherapy sequencing approaches, targeted agents, and tumor treating field therapy, among others, in the setting of advanced pancreatic cancer, Recommend appropriate therapeutic platforms across multiple lines of therapy for patients with advanced pancreatic cancer based on available evidence, guideline recommendations, and disease- and patient-specific characteristics, Identify patients with pancreatic cancer who are candidates for experimental therapy in a clinical trial, Manage adverse events associated with established cytotoxic and emerging therapies for pancreatic cancer.

Go online to PeerView.com/RRU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Pancreatic cancer has retained its fearsome reputation amidst the clinical advances made in recent years in other solid tumor settings, and it is now the fourth leading cause of cancer death in men and women in the United States. But recently, new science has taken important steps in meeting the challenges posed by this disease. Beginning with the validation of modern chemotherapy platforms, which now can be sequenced to improve clinical benefits, clinicians are increasingly able to select more potent—and soon, more targeted—options for disease management. In the wake of these advances, other innovative therapies are being rapidly developed, from stroma- and BRCA-targeting agents, to immunotherapy and tumor treating fields. In this PeerView CaseBook on-demand activity based on a recent live symposium held at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, our expert panel profiles the modern management of pancreatic cancer, including the evidence for more personalized approaches to treatment decision-making across the disease spectrum. The panelists highlight new directions in therapeutic sequencing, explore the role of clinical trials as a driver for validating innovative strategies, and use real-world cases to crystalize strategies for initial therapy selection and sequencing, the function of biomarker testing, and patient referral to clinical trials. This engaging CaseBook activity also highlights important “patient voice” materials developed in collaboration with Let's Win, an online community (letswinpc.org) for sharing information about innovative, science-based treatments for Pancreatic Cancer. Let's Win is an affiliate of the Lustgarten Foundation. Upon completion of this activity, participants will be able to: Summarize recent evidence on the use of modern cytotoxic platforms and chemotherapy sequencing approaches, targeted agents, and tumor treating field therapy, among others, in the setting of advanced pancreatic cancer, Recommend appropriate therapeutic platforms across multiple lines of therapy for patients with advanced pancreatic cancer based on available evidence, guideline recommendations, and disease- and patient-specific characteristics, Identify patients with pancreatic cancer who are candidates for experimental therapy in a clinical trial, Manage adverse events associated with established cytotoxic and emerging therapies for pancreatic cancer.

Go online to PeerView.com/RRU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Pancreatic cancer has retained its fearsome reputation amidst the clinical advances made in recent years in other solid tumor settings, and it is now the fourth leading cause of cancer death in men and women in the United States. But recently, new science has taken important steps in meeting the challenges posed by this disease. Beginning with the validation of modern chemotherapy platforms, which now can be sequenced to improve clinical benefits, clinicians are increasingly able to select more potent—and soon, more targeted—options for disease management. In the wake of these advances, other innovative therapies are being rapidly developed, from stroma- and BRCA-targeting agents, to immunotherapy and tumor treating fields. In this PeerView CaseBook on-demand activity based on a recent live symposium held at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, our expert panel profiles the modern management of pancreatic cancer, including the evidence for more personalized approaches to treatment decision-making across the disease spectrum. The panelists highlight new directions in therapeutic sequencing, explore the role of clinical trials as a driver for validating innovative strategies, and use real-world cases to crystalize strategies for initial therapy selection and sequencing, the function of biomarker testing, and patient referral to clinical trials. This engaging CaseBook activity also highlights important “patient voice” materials developed in collaboration with Let's Win, an online community (letswinpc.org) for sharing information about innovative, science-based treatments for Pancreatic Cancer. Let's Win is an affiliate of the Lustgarten Foundation. Upon completion of this activity, participants will be able to: Summarize recent evidence on the use of modern cytotoxic platforms and chemotherapy sequencing approaches, targeted agents, and tumor treating field therapy, among others, in the setting of advanced pancreatic cancer, Recommend appropriate therapeutic platforms across multiple lines of therapy for patients with advanced pancreatic cancer based on available evidence, guideline recommendations, and disease- and patient-specific characteristics, Identify patients with pancreatic cancer who are candidates for experimental therapy in a clinical trial, Manage adverse events associated with established cytotoxic and emerging therapies for pancreatic cancer.

Go online to PeerView.com/RRU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Pancreatic cancer has retained its fearsome reputation amidst the clinical advances made in recent years in other solid tumor settings, and it is now the fourth leading cause of cancer death in men and women in the United States. But recently, new science has taken important steps in meeting the challenges posed by this disease. Beginning with the validation of modern chemotherapy platforms, which now can be sequenced to improve clinical benefits, clinicians are increasingly able to select more potent—and soon, more targeted—options for disease management. In the wake of these advances, other innovative therapies are being rapidly developed, from stroma- and BRCA-targeting agents, to immunotherapy and tumor treating fields. In this PeerView CaseBook on-demand activity based on a recent live symposium held at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, our expert panel profiles the modern management of pancreatic cancer, including the evidence for more personalized approaches to treatment decision-making across the disease spectrum. The panelists highlight new directions in therapeutic sequencing, explore the role of clinical trials as a driver for validating innovative strategies, and use real-world cases to crystalize strategies for initial therapy selection and sequencing, the function of biomarker testing, and patient referral to clinical trials. This engaging CaseBook activity also highlights important “patient voice” materials developed in collaboration with Let's Win, an online community (letswinpc.org) for sharing information about innovative, science-based treatments for Pancreatic Cancer. Let's Win is an affiliate of the Lustgarten Foundation. Upon completion of this activity, participants will be able to: Summarize recent evidence on the use of modern cytotoxic platforms and chemotherapy sequencing approaches, targeted agents, and tumor treating field therapy, among others, in the setting of advanced pancreatic cancer, Recommend appropriate therapeutic platforms across multiple lines of therapy for patients with advanced pancreatic cancer based on available evidence, guideline recommendations, and disease- and patient-specific characteristics, Identify patients with pancreatic cancer who are candidates for experimental therapy in a clinical trial, Manage adverse events associated with established cytotoxic and emerging therapies for pancreatic cancer.

Go online to PeerView.com/RRU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Pancreatic cancer has retained its fearsome reputation amidst the clinical advances made in recent years in other solid tumor settings, and it is now the fourth leading cause of cancer death in men and women in the United States. But recently, new science has taken important steps in meeting the challenges posed by this disease. Beginning with the validation of modern chemotherapy platforms, which now can be sequenced to improve clinical benefits, clinicians are increasingly able to select more potent—and soon, more targeted—options for disease management. In the wake of these advances, other innovative therapies are being rapidly developed, from stroma- and BRCA-targeting agents, to immunotherapy and tumor treating fields. In this PeerView CaseBook on-demand activity based on a recent live symposium held at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, our expert panel profiles the modern management of pancreatic cancer, including the evidence for more personalized approaches to treatment decision-making across the disease spectrum. The panelists highlight new directions in therapeutic sequencing, explore the role of clinical trials as a driver for validating innovative strategies, and use real-world cases to crystalize strategies for initial therapy selection and sequencing, the function of biomarker testing, and patient referral to clinical trials. This engaging CaseBook activity also highlights important “patient voice” materials developed in collaboration with Let's Win, an online community (letswinpc.org) for sharing information about innovative, science-based treatments for Pancreatic Cancer. Let's Win is an affiliate of the Lustgarten Foundation. Upon completion of this activity, participants will be able to: Summarize recent evidence on the use of modern cytotoxic platforms and chemotherapy sequencing approaches, targeted agents, and tumor treating field therapy, among others, in the setting of advanced pancreatic cancer, Recommend appropriate therapeutic platforms across multiple lines of therapy for patients with advanced pancreatic cancer based on available evidence, guideline recommendations, and disease- and patient-specific characteristics, Identify patients with pancreatic cancer who are candidates for experimental therapy in a clinical trial, Manage adverse events associated with established cytotoxic and emerging therapies for pancreatic cancer.

Investigators Discuss the Available Data and Clinical Factors That Shape the Management of GI Cancers. Interview with Johanna C Bendell, MD conducted by Neil Love, MD. Produced by Research To Practice.

Investigators Discuss the Available Data and Clinical Factors That Shape the Management of GI Cancers. Interview with Johanna C Bendell, MD conducted by Neil Love, MD. Produced by Research To Practice.

Conversations with Oncology Investigators. Proceedings from a Clinical Investigator Think Tank featuring Johanna C Bendell, Charles S Fuchs, Richard M Goldberg, J Randolph Hecht, Eileen M O'Reilly and Philip A Philip. Moderated by Neil Love, MD. Produced by Research To Practice.

Conversations with Oncology Investigators. Proceedings from a Clinical Investigator Think Tank featuring Johanna C Bendell, Charles S Fuchs, Richard M Goldberg, J Randolph Hecht, Eileen M O'Reilly and Philip A Philip. Moderated by Neil Love, MD. Produced by Research To Practice.

Conversations with Oncology Investigators. Proceedings from a Clinical Investigator Think Tank featuring Johanna C Bendell, MD, Charles S Fuchs, MD, MPH, Richard M Goldberg, MD, J Randolf Hecht, MD, Eileen M O'Reilly, MD and Philip A Philip, MD, PhD. Moderated by Neil Love, MD. CME Information and Program PDF. Produced by Research To Practice.

Conversations with Oncology Investigators. Proceedings from a Clinical Investigator Think Tank featuring Johanna C Bendell, MD, Charles S Fuchs, MD, MPH, Richard M Goldberg, MD, J Randolf Hecht, MD, Eileen M O'Reilly, MD and Philip A Philip, MD, PhD. Moderated by Neil Love, MD. CME Information and Program PDF. Produced by Research To Practice.

Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care. Interview with Johanna C Bendell, MD conducted by Neil Love, MD. Produced by Research To Practice.

Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care. Featuring interviews with George D Demetri, MD, Johanna C Bendell, MD, Norman Wolmark, MD and Ghassan Abou-Alfa, MD conducted by Neil Love, MD. CME Information and Program PDF. Produced by Research To Practice.

Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care. Interview with Johanna C Bendell, MD conducted by Neil Love, MD. Produced by Research To Practice.

Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care. Featuring interviews with George D Demetri, MD, Johanna C Bendell, MD, Norman Wolmark, MD and Ghassan Abou-Alfa, MD conducted by Neil Love, MD. CME Information and Program PDF. Produced by Research To Practice.